Member Info for Kashdog

Chester, it might be wishful thinking as I am not sure that 16 patients in a phase 1 trial is enough to provide reliable results maybe someone can verify that. Hopefully, more than 16 were recruited but my understanding is that a phase 2 trial would require between 300-3,000 patients. If I am wrong then I would be happy to be corrected.
I am also not sure where, or how, the Covid 100 day development of vaccines applies and what the minimum numbers are with that.

Ol’blue, Goldman Sachs do not own any shares in this company. The majority shareholder with 11.43% is Align Research.
You have interpreted old news about an ex employee of Goldman Sachs joining Pathfinder Minerals falsely. I suspect to try and ramp yet another losing share for you.
This from last year!…” The company, which is in dispute over its licences in the country, has made Jonathan Summers - a fomer managing director at Goldman Sach and currently on the boards of medical cannabis company EXMceuticals and ecommerce businss Mocha Holdings - an independent non-executive director with immediate effect.
He will waive a salary for the first twelve months but has been awarded options over 6mln shares exercisable at 0.55p a share. The company will seek shareholder approval for another 6mln exercisable at 1.25p.”

Ol’blue, did you research Jarvis Investment Management?…perhaps you should have!.. some of their clients are not very happy!.. good quality research will save you money as well as make you money!.. you ain’t quite getting it yet are you?

Ol’ blue, you appear to me to be a reckless gambler..I thought you showed some sense in divesting from this stock but noting your “gamble” on Pathfinder Minerals, I did some initial research and cannot believe you’ve thrown your money at another hospital case in Mozambique. Another AIM company embroiled in litigation that will end up getting zilch from the Mozambique government.
Look at their chart, apart from a blip north in Dec / Jan, it has headed south in the last year.
It’s another loser for you!
I suspect you are not one to take advice so I won’t offer any, I just hope you are using money you can afford to lose.

Not sure when Sanofi and GSK started their efforts in relation to Scancell’s efforts but this announced today!!

“Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus)
* In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:
* 100% efficacy against severe COVID-19 disease and hospitalizations
* 75% efficacy against moderate or severe COVID-19 disease
* 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern”
* Favorable safety profile following both primary series and booster vaccinations.

This from Corcel “News” less than 3 Months ago!
“ Corcel PLC - London-based mineral explorer and developer with interests in battery metals and flexible energy generation & storage - C4 Energy purchases GBP126,917 of principal interest in Corcel's debt.
In addition, Corcel will make a payment of GBP100,000 to reduce its existing debt position and has agreed to refinance the balance to December 23, 2022. Will also issue to lenders 3.8 million warrants with a 1.5 pence strike price.”
Ring any bells?

Ol’ blue, you do know that Parsons is Executive Chairman at Corcel don’tcha?

I never realised that the SAHPRA CEO was linked to Nottingham University!
She is one of the speakers at the SAHPRA event!

Bio

Dr Boitumelo Semete-Makokotlela - SAHPRA CEO
Dr Boitumelo Semete-Makokotlela is the CEO of the South African Health Products Regulator. She has a Ph.D. (Biochemistry) and also holds MSc in Management Finance and Investment. She is also a fellow of the African Leadership Initiative. Within the technology innovation space, she managed a biotechnology incubator at The Innovation Hub Management Company. She was with McKinsey & Company for 2 years as a McKinsey Leadership Fellow. Prior to that, she was at the CSIR as a Senior Researcher. She completed her postdoctoral research at the University of Nottingham and EPFL, Switzerland.

Might be interesting and I imagine that SCLP would get a mention as this is the SA organisation that approved the Covidity trial!

Update on COVID-19 Therapies
SAHPRA will be joined by experts to discuss the latest updates on Covid-19 therapies.
Date: Monday, 21 February 2022
Time: 11h30 - 12h30

Bored now!…I’ll look in next week! :-)

So what offended you Rats?
I had a view on Crumbs post, I don’t believe it was offensive, I am sure he can look after himself…feel free to delete this as well if you want to!

So my last post deleted!…probably by some small minded, overly sensitive, self important prima Donna who has a desperate need to control this BB…Now I wonder who that could be?…I’m still chuckling! :-D

With you all the way Bahria :-D :-D

Bahria, for the avoidance of doubt, my tongue in cheek question (meant to be funny) was referring to the following:
“ The 2018 Australian ball-tampering scandal, also known as the Sandpapergate scandal, was a cricket cheating scandal surrounding the Australian national cricket team. In March 2018, during the third Test match against South Africa at Newlands in Cape Town, Cameron Bancroft was caught by television cameras trying to rough up one side of the ball with sandpaper to make it swing in flight.[1] Captain Steve Smith and vice-captain David Warner were found to be involved and all three received unprecedented sanctions from Cricket Australia”

Bahria, is it possible IK has some Australian in him?

He’d best pull his finger out and get on with it then Bahria!…:-)

Fear of missing out (FOMO) is a poor investment reason but I admit that it has influenced me with this one. I am holding multi millions for a few thousand quid.
I won’t starve if it fails.
I did some research that convinced me this has potential but Director buy ins was key and the relatively “speedy” progress in Australia is positive.
However, this has all the hallmarks of a precarious AIM project!…a rich Middle Eastern gentleman is the main investor, insignificant institutional investment, geographical diverse and no income, only operating costs and salaries … does that sound familiar?
… but hey ho!… it doesn’t hurt to dream, it may be the one in a million that comes good and we can then buy our own airplanes and Islands….Yeeehaw!!

Cleaner, I don’t fully agree with your 14 points…it looks like a ramp.
Item 1 “positive results” ?? I am not aware of that as a fact, I am aware that no adverse effects have been noted after 16 trial patients.
Item 3 “Further trials in the UK” are not currently approved
Item 5 BioNTech’s share price is not relative to SCLP
Item 6 No reason they cannot buy that I am aware of (I admit I am not fully aware of the rules,)
Item 8 No evidence to support that we are “Leaders” it is an opinion… if it was a “proven” fact..then the SP would be a lot higher.
I am not negative, I remain a “strong buy” but I prefer to look at this with a tinge of reality.
I believe SCLP is a relatively “low risk” investment but investors should occasionally remind themselves that there are no guarantees. It would not take much in the way of “bad news” to dramatically move the SP down, maybe temporarily because of the multi-platforms but anything negative from trials on more than one front would see the major investors heading for the exit.
A concern for me is the speed of progress..it’s not weeks or months..it’s years and years to achieve anything …. and nothing to date is making any returns.
Having said all of the above, I remain optimistic ….and greedy!!

A simplistic view perhaps but the company is not earning, has operating costs and has diluted so nothing except potential at this point in time.
The expectation that an RNS essentially stating this, although not in those words, would have a dramatic impact, is a tad unrealistic.
The SP, in my view, will move north when news indicating that Amapa is stirring into production is released.
A slow ramp up of mine activity might mean a slow ramp up of the SP but it could be dramatic depending on Ore price movement, transportation availability and rates and continuing supply chain issues….a strong buy in my opinion!

More dilution and 242,424 issued to themselves as “Staff”…there are no staff except for the board. Shocking really. The only consolation is that when this company stops being a “going concern” and delists, those shares will cease to exist and be worth nothing …but these b@st@rds will have dumped them before then because they are the only ones that know precisely when it will happen.